Page 11 - Exact Sciences News Today

If we are to achieve the clinical and economic benefits of primary care and care continuity, the implementation and evaluation of strategies that reward clinicians and patients are warranted.

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fourteen analysts that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price objective among […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) General Counsel James Herriott sold 415 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $25,522.50. Following the completion of the sale, the general counsel now directly owns 6,943 […]

Exact Sciences ( NASDAQ:EXAS ) Full Year 2023 Results Key Financial Results Revenue: US$2.50b (up 20% from FY 2022...

Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) Director D Scott Coward sold 706 shares of the stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $43,419.00. Following the completion of the transaction, the director now directly owns 43,122 shares in […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) Director D Scott Coward sold 706 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $43,419.00. Following the sale, the director now owns 43,122 shares in the company, […]

Insightful Analysis of Exact Sciences Corp's Financial Health and Market Position

Exact Sciences (EXAS) delivered earnings and revenue surprises of 49.06% and 2.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

EXAS earnings call for the period ending December 31, 2023.